Viatris (VTRS) Capital Expenditures Growth (1y) (2021 - 2026)
Viatris (VTRS) Capital Expenditures Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.88 Bn | 87.01 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | 32.28% |
| 3 | Zoetis | 32.31 Bn | 30.37 Bn | 1.62 Bn | -38.20% |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | -15.72% |
| 5 | United Therapeutics | 23.07 Bn | 20.91 Bn | 648.10 Mn | 32.98% |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - | - |
| 7 | Viatris | 20.27 Bn | 18.47 Bn | 1.16 Bn | -6.34% |
| 8 | Neurocrine Biosciences | 17.92 Bn | 16.61 Bn | 800.70 Mn | -86.92% |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | -21.54% |
| 10 | Vireo Growth | 10.52 Bn | 10.37 Bn | 59.30 Mn | 881.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.34% |
| Dec 31, 2025 | 39.96% |
| Sep 30, 2025 | 12.73% |
| Jun 30, 2025 | -10.03% |
| Mar 31, 2025 | -14.46% |
| Dec 31, 2024 | -15.17% |
| Sep 30, 2024 | -19.71% |
| Jun 30, 2024 | -13.27% |
| Mar 31, 2024 | 4.18% |
| Dec 31, 2023 | 7.68% |
| Sep 30, 2023 | -7.70% |
| Jun 30, 2023 | -19.19% |
| Mar 31, 2023 | -25.89% |
| Dec 31, 2022 | -22.14% |
| Sep 30, 2022 | -14.13% |
| Jun 30, 2022 | -6.05% |
| Mar 31, 2022 | 30.30% |
| Dec 31, 2021 | 68.86% |
| Mar 31, 2021 | 14.06% |